+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05579366

Phase 12 Study Evaluating Rina-S in Locally Advanced and Metastatic Solid Tumors Including Ovarian, Breast, Lung, and Endometrial Cancers

Led by Genmab · Updated on 2026-11-04

952

Participants Needed

67

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying Rina-S, a targeted antibody-drug conjugate aimed at treating participants with solid tumors that are either metastatic or cannot be removed by surgery. This Phase 12 trial evaluates Rina-Ss safety, side effects, how the body processes the drug, and its potential anti-tumor effects across various cancers including ovarian, endometrial, breast, lung, and mesothelioma. Participants receive Rina-S either alone or in combination with other cancer drugs like carboplatin, bevacizumab, pembrolizumab, or CYP3A4 inhibitors such as erythromycin or itraconazole. The study includes multiple parts, each focusing on different tumor types or combinations of therapies. Treatment continues until disease progression, unacceptable side effects, withdrawal of consent, or other specified reasons. During the study, participants undergo regular evaluations including monitoring for side effects, tumor response assessments using imaging criteria, and blood tests to measure drug levels and antibodies. Safety and effectiveness data are collected for up to about one year, with some outcomes followed for up to two years. Participants remain under medical supervision throughout the trial duration, which runs until March 2029.

CONDITIONS

Brief Title

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Research Team

G

Genmab Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here